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ABSTRACT
Background: Significant clinical heterogeneity within contemporary risk group is well 
known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study 
aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to 
discern between favorable and non-favorable risk in patients with IRPCa.
Methods: We retrospectively reviewed the data of 203 IRPCa patients who underwent 
extraperitoneal robot-assisted radical prostatectomy (RARP) performed by a single surgeon. 
Pathologic favorable IRPCa was defined as a Gleason score ≤ 6 and organ-confined stage at 
surgical pathology. The CAPRA score was compared with two established criteria for the 
within-group discrimination ability.
Results: Overall, 38 patients (18.7% of the IRPCa cohort) had favorable pathologic features 
after RARP. The CAPRA score significantly correlated with established criteria I and II and 
was inversely associated with favorable pathology (all P < 0.001). The area under the receiver 
operating characteristic curve for the discriminative ability between favorable and non-
favorable pathology was 0.679 for the CAPRA score and 0.610 and 0.661 for established 
criteria I and II, respectively. During a median 37.8 (interquartile range, 24.6–60.2) months 
of follow-up, 66 patients (32.5%) experienced biochemical recurrence (BCR). Cox regression 
analysis revealed that the CAPRA score, as a continuous sum score model or 3-group risk 
model, was an independent predictor of BCR after RARP.
Conclusion: The within-group discrimination ability of preoperative CAPRA score might help 
in patient counseling and selecting optimal treatments for those with IRPCa.
Keywords: Prostate-specific Antigen; Prostate-specific Antigen Density; Prostatic 
Neoplasms; Prostatectomy; Biochemical Recurrence
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INTRODUCTION
Patients with prostate cancer (PCa) have extremely heterogeneous clinical courses, ranging 
from indolent and organ-confined to aggressive, metastatic, lethal diseases.1-3 Physicians 
often use risk stratification systems to determine the stage of cancer and design a proper 
treatment approach.4 At diagnosis, PCa is usually classified into major risk categories (low, 
intermediate, and high) based on tumor, node, and metastasis (TNM) clinical stage, biopsy 
Gleason score, and pretreatment prostate-specific antigen (PSA) levels. The most widely used 
risk classification systems are the D'Amico classification5 and the National Comprehensive 
Cancer Network (NCCN) risk classification6 that equally assign weights to any combination 
of these three factors, creating an extremely heterogeneous mix of patients within each of 
the three categories, particularly for those with intermediate-risk prostate cancer (IRPCa).7 
Biochemical recurrence (BCR) rates following definitive primary treatment for IRPCa vary 
dramatically, with 5-year rates ranging from 2% to 70%.8-11 This heterogeneity of clinical 
courses suggests that there are subsets of IRPCa patients with unfavorable prognoses. 
Zumsteg and colleagues7 recently proposed substratifying tools to classify patients as 
having unfavorable or favorable IRPCa using three clinical factors that are not included in 
the contemporary risk stratification system, such as primary Gleason pattern, percentage 
of positive biopsy cores, and the number of intermediate-risk factors. Given that different 
treatment options are recommended according to the risk stratification, there is a great need 
for reliable risk substratifying tools.
The University of California San Francisco (UCSF) Cancer of the Prostate Risk Assessment 
(CAPRA) score was developed to facilitate risk stratification.12 The CAPRA score is easily 
calculated from routinely collected clinical variables: PSA, biopsy Gleason score, age, 
clinical T stage, and percentage of positive biopsy cores.13 This prediction model has been 
extensively validated in the assessment of metastasis and mortality across multiple treatment 
modalities.14-18 Interestingly, we recognized similarities between the substratifying tools 
adopted to use established criteria and pretreatment variables in the CAPRA score.7,19 The 
primary Gleason pattern, percentage of positive biopsy cores, and numbers of intermediate-
risk factors (PSA level > 10 but ≤ 20 ng/mL, a biopsy Gleason score 7, or cT2b-c) were also 
employed to calculate the CAPRA score. Thus, we hypothesized that because the CAPRA 
score incorporates additional informative clinical variables it could be used to stratify 
intermediate-risk patients into different prognostic groups.
The present study aimed to assess the clinical applicability of the CAPRA score to subclassify 
patients with IRPCa into different prognostic groups. We examined the consistency between 
CAPRA score and established criteria and compared its ability to predict favorable pathology.
METHODS
Study population and surgery
We retrospectively reviewed the data of 1,086 PCa patients who underwent robot-assisted 
radical prostatectomy (RARP) performed by a single surgeon at Severance Hospital between 
January 2007 and December 2012. Among all RARP cases, 19.6% of patients met the criteria of 
IRPCa according to the D'Amico classification (clinical stage T2b, PSA levels between 10 and 
20, or Gleason score of 7).5 After excluding patients who received neo-adjuvant treatment or 
adjuvant radiotherapy and those with missing variables, 203 subjects met inclusion criteria.
2/9https://jkms.org https://doi.org/10.3346/jkms.2018.33.e36
Risk Assessment Score for Intermediate-Risk Prostate Cancer
RARP was carried out using our standardized extraperitoneal technique.20 Clinical staging 
was assigned by the attending urologist according to the 2002 TNM system. Biopsy and 
pathological grading were performed according to the Gleason grading system, and Gleason 
scores were assigned by genitourinary pathologists.
Data collection and definition
Preoperative characteristics, including clinical stage, PSA, and prostate biopsy findings 
were calculated to determine the CAPRA/Cancer of the Prostate Risk Assessment Post-
Surgical (CAPRA-S) score. Pathologic favorable IRPCa was defined as a Gleason score ≤ 6 
and organ-confined stage at surgical pathology. BCR was defined as two consecutive PSA 
values ≥ 0.2 ng/mL at any time postoperatively or any additional treatment more than 6 
months after RARP. The established criteria for unfavorable IRPCa were defined by criteria 1 
(primary Gleason pattern of 4 or ≥ 2 intermediate-risk factors)19 and criteria 2 (criteria 1, and 
percentage of positive biopsy cores ≥ 50%).7
Statistical analysis
The CAPRA scores were calculated for a continuous sum score model (range, 0–10) and 
3-group risk model as low (CAPRA 0 to 2), intermediate (CAPRA 3 to 5), and high (CAPRA 6 
to 10). We compared the discriminating performance of CAPRA with established criteria for 
predicting pathologic outcome with receiver operating curve (ROC) analysis. The Kaplan-
Meier method and the log-rank statistic were used to test for BCR free survival differences 
according to the CAPRA score. Hazard ratios for BCR following RARP were estimated using 
Cox proportional hazards regression analysis according to the CAPRA scores. Statistical 
significance was considered at P < 0.05 (two-sided tests). Statistical analysis was performed 
using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).
Ethics statement
The study was carried out in agreement with the applicable laws and regulations, good 
clinical practices, and ethical principles as described in the Declaration of Helsinki. The 
Institutional Review Board of the Severance Hospital approved the study protocol (Approval 
number: 4-2014-0619). The board exempted informed consent.
RESULTS
Baseline characteristics
Table 1 lists the baseline characteristics of the 203 IRPCa patients who met the inclusion criteria 
and underwent extraperitoneal RARP performed by a single surgeon. The median prebiopsy PSA 
and prostate-specific antigen density (PSAD) were 7.92 ng/mL and 0.27 ng/mL/g, respectively. 
Overall, 142 (70%) of IRPCa patients had a biopsy Gleason score of 7, and 65 patients had a 
primary Gleason pattern scored as 4. After RARP, about half of patients were confirmed to have 
organ-confined disease, and one-fourth of patients had a low-grade cancer (Gleason score ≤ 6). 
Overall, 38 (18.7%) patients had favorable pathologic features after RARP (Table 2).
Discriminative ability between favorable and non-favorable pathology
The distribution of the summed CAPRA scores for our cohort is listed in Table 3. The vast 
majority of patients (97.0%) had a CAPRA score from 2 to 6; only 1.0% had a score greater 
than 7, and none had a score greater than 8. The CAPRA score was well correlated with 
established criteria I and II (linear by linear association, P < 0.001). None of the patients who 
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have a summed CAPRA score greater than 5 met the established criteria I and II for favorable 
IRPCa. The pathologic assessment of the summed CAPRA scores inversely correlated with 
favorable pathology (linear by linear association, P < 0.001) (Table 4). The areas under the 
ROC of discriminative ability between favorable and non-favorable pathology were 0.679 for 
CAPRA score and 0.610 and 0.661 for established criteria I and II, respectively (Fig. 1).
Prediction of BCR after RARP
During a median follow-up of 37.8 (interquartile range, 24.6–60.2) months, 66 (32.5%) 
patients experienced BCR. There were significant differences with regard to BCR survival when 
categorized by 3-group risk model according to the CAPRA score (log-rank P < 0.001) (Fig. 
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Table 1. Baseline clinicopathologic characteristics
Baseline characteristics Values
No. of patients 203
Follow-up period, mon 37.8 (24.6–60.2)
Age, yr 65.0 (60.0–70.0)
BMI, kg/m2 24.2 (22.4–25.6)
PSA, ng/mL 7.92 (5.59–11.93)
PSAD, ng/mL/g 0.27 (0.19–0.38)
Biopsy Gleason score
5 2 (1.0)
6 59 (29.1)
7 (3 + 4) 77 (37.9)
7 (4 + 3) 65 (32.0)
Clinical T stage
T1c 93 (45.8)
T2a 73 (36.0)
T2b 37 (18.2)
Values are presented as median (IQR) or number (%).
BMI = body mass index, PSA = prostate-specific antigen, PSAD = prostate-specific antigen density, IQR = 
interquartile range.
Table 2. Pathologic outcomes of RP
Pathologic outcomes Values
High-grade PIN 120 (59.1)
Lymphovascular invasion 10 (4.9)
Perineural invasion 113 (59.1)
Gleason score
5 1 (0.5)
6 52 (25.6)
7 (3 + 4) 76 (37.4)
7 (4 + 3) 60 (29.6)
8 9 (4.4)
9 5 (2.5)
Pathologic T stage
T2a 25 (12.3)
T2b 13 (6.4)
T2c 65 (32.0)
T3a 88 (43.3)
T3b 9 (4.4)
T4 3 (1.5)
Positive surgical margin 53 (26.1)
Favorable IRPCa
RP pathologya 38 (18.7)
Established criteria I 108 (53.2)
Established criteria II 75 (36.9)
Values are presented as number (%).
RP = radical prostatectomy, PIN = prostatic intraepithelial neoplasia, IRPCa = intermediate-risk prostate cancer.
aFavorable pathology was defined as a Gleason score ≤ 6 and organ-confined cancer as detected by surgical pathology.
2). In the continuous CAPRA sum score model, the hazard ratio of BCR per 1 group increase 
was 1.415 (95% confidence interval [CI], 1.185–1.691). The 3-group risk model also showed 
statistical significance in terms of BCR, the hazard ratios of a BCR within intermediate- and 
high-risk groups compare to low-risk group were 3.950 (95% CI, 1.210–12.891) and 7.524 (95% 
CI, 2.291–24.712), respectively (Table 5).
DISCUSSION
In this study, we assessed the clinical applicability of the CAPRA score for risk stratification 
of patients with contemporary IRPCa. The CAPRA scoring system showed comparable 
accuracy for pathologic outcomes compared to the established criteria, and was found to be a 
significant predictor of BCR as a continuous sum score model or 3-group risk model.
Clinical heterogeneity among intermediate- or high-risk patients defined by the traditional 
three-group risk stratification methods such as D'Amico and the NCCN 2012 classifications 
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Table 3. Distribution of the data according to the CAPRA scores
Classifications Variables Level (point) No. (%)
CAPRA score PSA at diagnosis, ng/mL 2.0–6.0 (0) 58 (28.6)
6.1–10.0 (1) 66 (32.5)
10.1–20.0 (2) 79 (38.9)
20.1–30.0 (3) 0 (0)
> 30 (4) 0 (0)
Biopsy Gleason score 1–3/1–3 (0) 61 (30.0)
1–3/4–5 (1) 77 (37.9)
4–5/1–5 (3) 65 (32.0)
Clinical T stage T1/T2 (0) 203 (100)
T3a (1) 0 (0)
Percent positive biopsies, % < 34 (0) 150 (73.9)
≥ 34 (1) 53 (26.1)
Age at diagnosis, yr < 50 (0) 3 (1.5)
≥ 50 (1) 200 (98.5)
Summed CAPRA scores 1 4 (2.0)
2 36 (17.7)
3 69 (34.0)
4 39 (19.2)
5 30 (14.8)
6 23 (11.3)
7 2 (1.0)
CAPRA = Cancer of the Prostate Risk Assessment, PSA = prostate-specific antigen.
Table 4. Relationships between CAPRA score and established classification criteria I and II, and final pathology in patients with IRPCa
Classifications Established criteria I P Established criteria II P Final pathology P
Favorable Unfavorablea Favorable Unfavorableb Favorable Unfavorablec
CAPRA score < 0.001 < 0.001 < 0.001
1 4 (3.7) 0 (0) 3 (4.0) 1 (0.8) 1 (0) 3 (1.8)
2 31 (28.7) 5 (5.3) 20 (26.7) 16 (12.5) 14 (36.8) 22 (13.3)
3 61 (56.5) 8 (8.4) 43 (57.3) 26 (20.3) 14 (36.8) 55 (33.3)
4 12 (11.1) 27 (28.4) 9 (12.0) 30 (23.4) 4 (10.5) 35 (21.2)
5 0 (0) 30 (31.6) 0 (0) 30 (23.4) 3 (7.9) 27 (16.4)
6 0 (0) 23 (24.2) 0 (0) 23 (18.0) 2 (5.3) 21 (12.7)
7 0 (0) 2 (2.1) 0 (0) 2 (1.6) 0 (0) 2 (1.2)
Values are presented as number (%). P values were obtained by linear-by-linear association.
CAPRA = Cancer of the Prostate Risk Assessment, IRPCa = intermediate-risk prostate cancer.
Unfavorable disease was defined as aprimary Gleason pattern of 4 or ≥ 2 determinant of intermediate-risk factors at biopsy pathology; bcriteria I or percentage of 
positive biopsy cores ≥ 50%; cGleason score ≥ 7 or locally advanced disease at surgical pathology.
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Fig. 1. Discriminative ability between favorable (Gleason score ≤ 6 and prostate-confined disease at surgical 
pathology) and non-favorable pathology in patients with IRPCa. 
IRPCa = intermediate-risk prostate cancer, CAPRA = Cancer of the Prostate Risk Assessment, AUC = area under 
the receiver operating characteristics curve, CI = confidence interval.
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P = 0.013
Log-rank P < 0.001
Group 2 (CAPRA 3–5)
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P = 0.011
P < 0.001
Number at risk
Group 1 40 40 34 29 25 17 8 8 6 6 4 3 3 3 3 0 0 0
Group 2 108 98 86 73 62 51 45 37 30 28 21 18 14 5 4 0 0 0
Group 3 55 45 36 33 31 28 24 22 20 16 11 8 6 6 1 1 1 0
Fig. 2. Kaplan-Meier analysis of BCR-free survival categorized by 3-group risk model according to the CAPRA score in patients with IRPCa. 
BCR = biochemical recurrence, IRPCa = intermediate-risk prostate cancer, CAPRA = Cancer of the Prostate Risk Assessment.
has been recognized in several studies.21,22 The 5-year BCR rate following definitive primary 
treatment has been reported to range from 2% to 70% and 49% to 80% in intermediate- and 
high-risk PCas, respectively.23-25 Reese and colleagues1 highlighted heterogeneous pathologic 
and biochemical outcomes among intermediate- and high-risk groups. Specifically, significant 
within-group heterogeneity was observed according to the number of intermediate- and 
high-risk criteria. We also observed heterogeneous pathologic outcomes and BCR rates 
among IRPCa patients who underwent RARP. Numerous studies have attempted to establish 
new stratification that can be used to identify subsets of patients with relatively better and 
worse prognoses. Additional clinical factors such as proportion of positive biopsy cores, 
pretreatment PSA density, number of intermediate- and high-risk criteria, and primary 
Gleason pattern have been included in pretreatment prognostic models.7,26-28
Recently, two valuable prognostic models were described to stratify and identify subsets of 
patients with IRPCa with relatively better and worse prognoses. Jung and colleagues19 defined 
the unfavorable intermediate-risk disease as a primary Gleason pattern of 4 or multiple 
intermediate-risk factors. Another established criterion for unfavorable intermediate-risk 
disease was developed by Zumsteg and colleagues7; they added a proportion of positive 
biopsy cores ≥ 50% to a previous criterion to identify patients with unfavorable intermediate-
risk disease.
CAPRA is an easy-to-calculate risk score used to predict the preoperative probability of BCR-
free survival after radical prostatectomy (RP); it was introduced by Cooperberg et al.12,18 in 
2005. The sum of the point values for the five variables (preoperative PSA, biopsy Gleason 
score, clinical TNM stage, percentage of positive biopsy, and age at diagnosis) yields a score 
from 0 to 10, with a higher value associated with an increased risk of recurrence.13 This 
prognostic instrument has been extensively validated with regard to biochemical progression, 
local recurrence, distant metastasis, and prostate-cancer-specific mortality across multiple 
treatment modalities, but its within-group discrimination power has not been previously 
investigated. We found that CAPRA scores correlated well with both established criteria. 
Moreover, the pathologic outcomes of the summed CAPRA scores demonstrated an inverse 
correlation with favorable pathology.
The present study had a potential limitation. Any retrospective analysis of surgical patients will 
be fraught with selection bias. It only included cohort from a single tertiary institution and a 
single surgeon series. Thus, larger multicenter studies are needed to confirm the applicability of 
the CAPRA score for risk discrimination among contemporary IRPCa patients.
In conclusion, CAPRA score is a simple preoperative tool that can be readily applied in 
clinical practice to help risk-stratify heterogeneous IRPCa patients into different prognostic 
groups with regard to therapy planning and counseling.
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Table 5. Cox proportional hazards regression analysis for prediction of BCR after RP in patients with IRPCa
CAPRA models HR (95% CI) P
CAPRA sum score (continuous) 1.415 (1.185–1.691) < 0.001
3-group risk model
Low (CAPRA 0 to 2) - -
Intermediate (CAPRA 3 to 5) 3.950 (1.210–12.891) 0.023
High (CAPRA 6 to 10) 7.524 (2.291–24.712) 0.001
BCR = biochemical recurrence, RP = radical prostatectomy, IRPCa = intermediate-risk prostate cancer, CAPRA = 
Cancer of the Prostate Risk Assessment, HR = hazard ratio, CI = confidence interval.
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